Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
- PMID: 16098311
- DOI: 10.1016/j.amjcard.2005.04.019
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
Abstract
The most recent national survey of compliance with the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) guidelines was completed before ATP III and showed significant underachievement of low-density lipoprotein (LDL) cholesterol goals. The NCEP Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II was a national survey conducted in 2003. Of the 4,885 patients, 67% achieved their LDL cholesterol treatment goal, including 89%, 76%, and 57%, respectively, in the 0 or 1 risk factor, > or = 2 risk factors or coronary heart disease (CHD), and CHD risk equivalent categories. The percentage with triglyceride concentrations > or = 200 mg/dl (2.25 mmol/L) in each risk category who achieved their LDL cholesterol and non-high-density lipoprotein cholesterol goals was 64%, 52%, and 27%, respectively. Patients with diabetes (55%) and other CHD risk equivalents (40%) were less likely to have achieved their LDL cholesterol targets than those with CHD (62%). Of the 1,447 patients with cardiovascular disease, 75% could be classified as very high risk according to the new July 2004 NCEP Writing Group recommendations, and 17.8% of those at very high risk had an LDL cholesterol level of <70 mg/dl (<1.81 mmol/L). In conclusion, these results suggest improved lipid management compared with previous surveys. The largest treatment gaps were found for features new to ATP III as of July 2004, including goal achievement for patients with CHD risk equivalents and for non-high-density lipoprotein cholesterol targets. Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals.
Similar articles
-
Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey.Am Heart J. 2006 Nov;152(5):976-81. doi: 10.1016/j.ahj.2006.05.013. Am Heart J. 2006. PMID: 17070174
-
Non-high-density lipoprotein cholesterol: the forgotten therapeutic target.Am J Cardiol. 2005 Nov 7;96(9A):59K-64K; discussion 34K-35K. doi: 10.1016/j.amjcard.2005.08.009. Epub 2005 Oct 21. Am J Cardiol. 2005. PMID: 16291016 Review.
-
Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines.Am J Cardiol. 2005 Dec 15;96(12):1674-80. doi: 10.1016/j.amjcard.2005.07.079. Epub 2005 Nov 2. Am J Cardiol. 2005. PMID: 16360356 Clinical Trial.
-
Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.Am J Geriatr Pharmacother. 2005 Dec;3(4):218-28. Am J Geriatr Pharmacother. 2005. PMID: 16503317 Clinical Trial.
-
New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III.Am J Manag Care. 2002 Sep;8(12 Suppl):S301-7. Am J Manag Care. 2002. PMID: 12240701 Review.
Cited by
-
Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction.Am Heart J. 2013 Jan;165(1):26-33.e3. doi: 10.1016/j.ahj.2012.10.005. Epub 2012 Nov 17. Am Heart J. 2013. PMID: 23237130 Free PMC article.
-
Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies.BMC Cardiovasc Disord. 2016 Apr 26;16:74. doi: 10.1186/s12872-016-0241-3. BMC Cardiovasc Disord. 2016. PMID: 27114245 Free PMC article. Review.
-
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.Mayo Clin Proc. 2010 Feb;85(2):122-8. doi: 10.4065/mcp.2009.0397. Mayo Clin Proc. 2010. PMID: 20118387 Free PMC article. Clinical Trial.
-
Applied pharmacogenomics in cardiovascular medicine.Annu Rev Med. 2014;65:81-94. doi: 10.1146/annurev-med-101712-122545. Epub 2013 Oct 2. Annu Rev Med. 2014. PMID: 24111889 Free PMC article. Review.
-
Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action.Core Evid. 2012;7:61-75. doi: 10.2147/CE.S26725. Epub 2012 Jul 12. Core Evid. 2012. PMID: 22936894 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical